Multi-ligand drug conjugates for targeted cancer therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug conjugate technologies, such as antibody-drug conjugates (ADCs) and ligand-drug conjugates (LDCs), face challenges including low specificity, high toxicity, and inefficient delivery due to complex design, large molecular weight, and limited bioavailability, leading to significant side effects and reduced therapeutic efficacy.
Innovation Solution
Development of multi-ligand drug conjugates (mLDCs) that combine multiple cell-interacting molecules, including ligands capable of binding to specific cell surface receptors, with a payload linked via linkers that facilitate targeted endocytosis, enhancing specificity and reducing toxicity by releasing the payload only within target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibody-drug conjugates (ADCs) are used to achieve high specificity to target cells, then the affinity to target cells is improved, but the toxicity to normal cells with the same target receptor increases
Solution Approach 1:
The invention segments the targeting function by using multiple different ligands (first ligand and second ligand) that bind to different cell surface receptors. This segmentation allows the conjugate to achieve specific recognition of target cells through combinatorial binding, while normal cells expressing only one receptor type will not bind with high affinity, thereby reducing off-target toxicity.
Solution Approach 2:
The invention creates a composite ligand system by combining multiple ligands with different specificities on a single conjugate molecule. This composite approach enables the drug conjugate to require simultaneous binding to multiple different receptors for stable attachment, significantly improving target cell specificity while sparing normal cells that lack the complete receptor profile.
2Productivity
If ligands are conjugated with highly effective drug molecules to improve therapeutic effect, then the efficacy is improved, but the toxicity increases resulting in animal poisoning death
Solution Approach 1:
The invention applies local quality by concentrating highly effective but toxic drug molecules (such as MMAE) exclusively at the target site through multi-ligand mediated specific binding. The drug is activated and released only where all required ligands bind simultaneously to the target cell surface, ensuring high therapeutic effect at the tumor site while maintaining low systemic toxicity that avoids animal death.
Solution Approach 2:
The multiple ligands act as intermediaries that bridge the highly toxic drug molecule and the target cell. These ligands control the localization and activation of the toxic drug, ensuring it only exerts its effect when properly positioned at the target cell through coordinated binding, thereby mediating between drug potency and safety.
3Measurement precision
If conventional ligand-drug conjugates are used to achieve targeted delivery, then the specificity is improved, but the bioavailability and stability are reduced
Solution Approach 1:
The invention merges multiple ligand-binding functions into a single conjugate molecule, creating a multi-functional entity that combines targeted recognition with enhanced stability. The combined structure of multiple ligands attached to a stable backbone (such as a dimeric or multimeric protein scaffold) provides both high specificity through multi-receptor binding and improved pharmacokinetic properties including enhanced serum stability and controlled bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multi-ligand approach improves therapeutic efficacy by increasing affinity and specificity for target cells, reducing side effects, and overcoming drug resistance, allowing for the efficient delivery of chemotherapeutic agents to cancer cells while minimizing harm to normal cells.
Implementation Method 1
ligands are either peptide or small molecule... ligands capable of binding to specific cell surface receptors... inducing endocytosis
Implementation Method 2
mLDCs capable of inducing endocytosis... releasing the payload only within target cells
Data Source
AI summary
A conjugate compounds or pharmaceutically acceptable salt thereof, comprises a payload and two or more kinds of cell-interacting molecules. The cell-interacting molecules are ligands capable of specifically binding to a cell surface receptor. A method of treating diseases, comprises delivering a payload to a subject.